Chelsia Wang

Dr. Chelsia Wang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
CWChelsia Wang
Chelsia Wang
PLPei Yu Lim
Pei Yu Lim
ATAndy Tan
Andy Tan
Adoptive cellular immunotherapy as a new paradigm to treat cancers is exemplified by the FDA approval of six chimeric antigen receptor-T cell therapies targeting hematological malignancies in recent years. Conventional αβ T cells applied in these therapies have proven efficacy but are confined almost exclusively to autologous use. When infused into patients with mismatched human leukocyte antigen, αβ T cells recognize tissues of such patients as foreign and elicit devastating graft-versus-host disease. Therefore, one way to overcome this challenge is to use naturally allogeneic immune cell types, such as γδ T cells. γδ T cells occupy the interface between innate and adaptive immunity and possess the capacity to detect a wide variety of ligands on transformed host cells. In this article, we review the fundamental biology of γδ T cells, including their subtypes, expression of ligands, contrasting roles in and association with cancer prognosis or survival, as well as discuss the gaps in knowledge pertaining to this cell type which we currently endeavor to elucidate. In addition, we propose how to harness the unique properties of γδ T cells for cellular immunotherapy based on lessons gleaned from past clinical trials and provide an update on ongoing trials involving these cells. Lastly, we elaborate strategies that have been tested or can be explored to improve the anti-tumor activity and durability of γδ T cells in vivo.

13 January 2023 in Cells
Verified
Journal Article
Open access
PDF file
CWChelsia Wang
Chelsia Wang
FCFONG CHAN Chan CHOY
FONG CHAN Chan CHOY
ASArleen Sanny
Arleen Sanny
TMTakashi Murakami
Takashi Murakami
ATAndy Tan
Andy Tan
KLKong-Peng Lam
Kong-Peng Lam
Immune checkpoint blockade (ICB) therapy involves the inhibition of immune checkpoint regulators which reverses their limitation of T cell anti-tumor responses and results in long-lasting tumor regression. However, poor clinical response or tumor relapse was observed in some patients receiving such therapy administered via antibodies blocking the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway alone or in combination, suggesting the involvement of additional immune checkpoints. CD96, a possible immune checkpoint, was previously shown to suppress natural killer (NK) cell anti-tumor activity but its role in human T cells remains controversial. Here, we demonstrate that CRISPR/Cas9-based deletion of CD96 in human T cells enhanced their killing of leukemia cells in vitro. T cells engineered with a chimeric antigen receptor (CAR) comprising human epidermal growth factor receptor 2 (EGFR2/HER2)-binding extracellular region and intracellular regions of CD96 and CD3ζ (4D5-96z CAR-T cells) were less effective in suppressing the growth of HER2-expressing tumor cells in vitro and in vivo compared with counterparts bearing CAR that lacked CD96 endodomain (4D5-z CAR-T cells). Together, our findings implicate a role for CD96 endodomain in attenuating T cell cytotoxicity and support combination tumor immunotherapy targeting multiple rather than single immune checkpoints.

13 June 2024 in Experimental Hematology
Verified
Journal Article
Closed access
KOKelly Ooi Kee Ong
Kelly Ooi Kee Ong
MMMichelle Meng Huang Mok
Michelle Meng Huang Mok
ANAkiko Niibori-Nambu
Akiko Niibori-Nambu
LDLinsen Du
Linsen Du
MYMasatoshi Yanagida
Masatoshi Yanagida
MOMotomi Osato
Motomi Osato

19 October 2025 in Genes to Cells
Verified
Journal Article
Closed access
GNGiselle Sek Suan Nah
Giselle Sek Suan Nah
JMJunichi Matsuo
Junichi Matsuo
ABAvinash Govind Bahirvani
Avinash Govind Bahirvani
SKShunichi Kimura
Shunichi Kimura
DCDesmond Wai Loon Chin
Desmond Wai Loon Chin
MOMotomi Osato
Motomi Osato